Introduction
Multiple sclerosis (MS), a chronic autoimmune disorder attacking the central nervous system, affects over 2.8 million people globally. Ublituximab—an investigational anti-CD20 monoclonal antibody—targets B-cells implicated in MS pathology. This analysis presents pivotal 5-year outcomes from the ULTIMATE open-label extension (OLE) study, building on initial phase 3 trials that demonstrated ublituximab’s superiority over teriflunomide (an established oral therapy) in reducing relapses and MRI lesions over two years.
Study Design and Patient Cohort
The ULTIMATE program included two identical double-blind trials (I and II) conducted from September 2017 to November 2020 across 150 centers. After completing the initial phase, 851 of 985 eligible adults with relapsing MS enrolled in the ongoing OLE. Participants either continued ublituximab (UBL-UBL group) or switched from teriflunomide to ublituximab (TER-UBL group). At the January 2024 data cutoff, 70% remained on treatment through Year 5. The cohort averaged 38.5 years old with 62.5% female representation, reflecting typical MS demographics.
Efficacy Outcomes Over Five Years
Patients switching from teriflunomide experienced a dramatic 58.4% reduction in annualized relapse rates (ARR) within one year (0.182 to 0.076). This improvement continued, reaching ARRs of 0.048 by Year 4 and 0.045 by Year 5. The continuous ublituximab group showed even lower ARRs: 0.053 in Year 3, declining to 0.020 by Year 5—translating to just one relapse per 50 patient-years. Disability outcomes significantly favored early ublituximab initiation: at Year 5, confirmed disability progression (CDP24) affected only 8.0% of UBL-UBL patients versus 14.3% in the TER-UBL group. Conversely, disability improvement (CDI24) occurred in 17.0% of continuous ublituximab recipients compared to 12.2% in the delayed-switch group.
Safety and Tolerability Profile
Safety data aligned with established anti-CD20 therapies. Exposure-adjusted serious infection rates (excluding COVID-19) were 2.10 (UBL-UBL) and 2.58 (TER-UBL) per 100 patient-years. Notably, immunoglobulin levels remained above clinically relevant thresholds throughout treatment. No correlation emerged between immunoglobulin concentrations and infection risk, reinforcing ublituximab’s manageable safety profile over extended use.
Clinical Implications and Future Directions
These findings underscore two critical principles in MS management: the superior long-term efficacy of high-potency B-cell therapies over moderate-efficacy agents like teriflunomide, and the advantage of early intervention. The 92% CDP24-free rate in continuous ublituximab recipients after five years represents unprecedented disease stability. Ongoing research will further evaluate ublituximab’s effects on brain volume loss, patient-reported outcomes, and real-world effectiveness across diverse populations.
Conclusion
The ULTIMATE OLE provides robust evidence for ublituximab as a durable, high-efficacy option for relapsing MS. Sustained reductions in relapse activity and disability progression over five years—combined with consistent safety data—support its potential as a first-line therapy. These results highlight the importance of early, potent immunomodulation in altering long-term disability trajectories in MS.